Skip to content
Clinical Trials – home

Donepezil Hydrochloride: A Comprehensive Guide for Patients

2 / 5
trials open to patients / all trials
5+
Countries

In short

This article examines the use of Donepezil Hydrochloride, also known as Aricept, in clinical trials for various neurological conditions. Donepezil is primarily studied for its effects on cognitive function, particularly in Alzheimer's disease, dementia with Lewy bodies, and vascular dementia. The trials explore its efficacy, safety, and potential benefits in improving memory, attention, and daily functioning in patients with these conditions.

At a glance

Main Conditions Studied
Alzheimer's Disease, Dementia with Lewy Bodies, Vascular Dementia, Autism Spectrum Disorder
Dosage Forms
Oral tablets (3 mg, 5 mg, 10 mg)
Primary Outcome Measures
Cognitive function (MMSE, ADAS-cog), Global clinical function (CIBIC-plus)
Secondary Outcome Measures
Activities of Daily Living, Neuropsychiatric symptoms, Quality of life
Special Populations
Patients with end-stage renal disease, Assisted living facility residents
Study Designs
Randomized controlled trials, Open-label studies, Pharmacokinetic studies
Duration of Trials
Ranging from 12 weeks to 24 weeks

What is Donepezil Hydrochloride?

Donepezil Hydrochloride, also known by its brand name Aricept or its research code E2020, is a medication primarily used to treat cognitive symptoms associated with various forms of dementia. It belongs to a class of drugs called acetylcholinesterase inhibitors, which work by increasing the levels of a certain chemical in the brain that is important for memory and thinking.

Conditions Treated by Donepezil

Donepezil is primarily used to treat the following conditions:

  • Alzheimer's Disease: It is most commonly prescribed for mild to severe Alzheimer's disease, a progressive brain disorder that affects memory, thinking, and behavior.
  • Dementia with Lewy Bodies (DLB): This is another type of dementia characterized by abnormal protein deposits in the brain.
  • Cognitive Deficits in Autism: Some research is exploring its potential use in treating cognitive problems associated with autism spectrum disorders.

How Donepezil Works

Donepezil works by inhibiting an enzyme called acetylcholinesterase. This enzyme normally breaks down acetylcholine, a neurotransmitter (chemical messenger) in the brain that is important for memory, thinking, and reasoning. By blocking this enzyme, donepezil helps to maintain higher levels of acetylcholine in the brain, which may improve or stabilize symptoms of dementia for some time.

Dosage and Administration

Donepezil is typically available in tablet form and is usually taken once daily. The dosage may vary depending on the condition being treated and the individual patient's response. Some common dosages include:

  • 5 mg daily, which may be increased to 10 mg daily after 4-6 weeks.
  • In some cases, doses may be increased up to 23 mg daily for moderate to severe Alzheimer's disease.

It's important to note that donepezil is also available as an orally disintegrating tablet, which can be taken with or without water. Always follow your doctor's instructions regarding dosage and administration.

Efficacy of Donepezil

The effectiveness of donepezil is typically measured using various cognitive and functional assessments. Some of the key measures used in clinical trials include:

  • Mini-Mental State Examination (MMSE): This test evaluates overall cognitive function, including orientation, memory, and attention. A higher score indicates better cognitive function.
  • Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog): This scale assesses a range of cognitive abilities. A lower score indicates better function.
  • Clinician's Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus): This measures overall clinical function based on both clinician and caregiver observations.

Studies have shown that donepezil can help improve or stabilize cognitive function and daily living activities in some patients with Alzheimer's disease and other forms of dementia. However, it's important to understand that while donepezil can help manage symptoms, it does not cure or stop the progression of these diseases.

Potential Side Effects

Like all medications, donepezil can cause side effects. Common side effects may include:

  • Nausea and vomiting
  • Loss of appetite
  • Diarrhea
  • Muscle cramps
  • Fatigue
  • Difficulty sleeping

More serious side effects, though less common, can include slow heartbeat, fainting, and severe stomach problems. It's important to report any side effects to your healthcare provider.

Use in Special Populations

Donepezil may be used with caution in certain populations:

  • Patients with kidney disease: Studies have been conducted to understand how donepezil is processed in patients with end-stage renal disease who are on hemodialysis.
  • Children and adolescents: While primarily used in adults, some research is exploring its potential use in children with autism spectrum disorders.

Ongoing Research

Researchers continue to study donepezil to understand its full potential. Some areas of ongoing research include:

  • Its use in combination with other medications for Alzheimer's disease.
  • Its potential effectiveness in treating cognitive deficits in autism.
  • Its use in treating oxaliplatin-induced peripheral neuropathy in cancer survivors.

As with any medication, it's crucial to discuss the potential benefits and risks of donepezil with your healthcare provider. They can provide personalized advice based on your specific health situation and needs.

Questions people often ask

Conditions where Donepezil Hydrochloride is being studied

Each condition opens its own overview and trial list

Trials with Donepezil Hydrochloride

Recruiting trials first

See all 5 →
Quick filters
  • Participants:Adults
  • Participants:Adults · Healthy volunteers
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).